Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01773122 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Pharmacokinetics of Dapsone in Acne Vulgaris
A Phase 1 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 1
- Development phase
- 77
- Enrollment target
NCT01773122 is a Phase 1 study that has completed, run by Allergan. The registered enrollment target is 77 participants.
The verdict
NCT01773122, a Phase 1 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 77 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of dapsone in subjects with acne vulgaris following 28 days of dosing.
Interventions
- DRUG Dapsone Formulation A
- DRUG Dapsone Formulation B
- DRUG Dapsone Formulation C
- DRUG Dapsone 5% Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2013-01-21 |
| Est. Completion | 2013-05-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01773122
The ClinicalTrials.gov registry entry for NCT01773122 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Dapsone Formulation A is the first listed.
NCT01773122 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01773122 about?
NCT01773122 is a clinical study titled "Safety, Tolerability, and Pharmacokinetics of Dapsone in Acne Vulgaris". This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of dapsone in subjects with acne vulgaris following 28 days of dosing.
What is the current status of trial NCT01773122?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2013-01-21. Estimated completion is 2013-05-05.
What interventions are being tested in trial NCT01773122?
The interventions under investigation include: Dapsone Formulation A (DRUG), Dapsone Formulation B (DRUG), Dapsone Formulation C (DRUG), Dapsone 5% Gel (DRUG).
Who is sponsoring clinical trial NCT01773122?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.